{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T15:37:49Z","timestamp":1791041869122,"version":"4.1.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2022,6,22]],"date-time":"2022-06-22T00:00:00Z","timestamp":1655856000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,6,22]],"date-time":"2022-06-22T00:00:00Z","timestamp":1655856000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["20K07139"],"award-info":[{"award-number":["20K07139"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1007\/s00277-022-04893-w","type":"journal-article","created":{"date-parts":[[2022,6,22]],"date-time":"2022-06-22T21:14:26Z","timestamp":1655932466000},"page":"2013-2019","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Low cerebrospinal fluid-to-plasma ratios of orally administered lenalidomide mediated by its low cell membrane permeability in patients with hematologic malignancies"],"prefix":"10.1007","volume":"101","author":[{"given":"Daisuke","family":"Ogiya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norie","family":"Murayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Kamiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rie","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sawako","family":"Shiraiwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rikio","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichiro","family":"Machida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei","family":"Tazume","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyoshi","family":"Ando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1068-4261","authenticated-orcid":false,"given":"Hiroshi","family":"Yamazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,22]]},"reference":[{"key":"4893_CR1","first-page":"491","volume":"15","author":"Y Kim","year":"2015","unstructured":"Kim Y, Schmidt-Wolf IG (2015) Lenalidomide in multiple myeloma ExpertRevAnticancer Ther 15:491\u2013497","journal-title":"Lenalidomide in multiple myeloma ExpertRevAnticancer Ther"},{"key":"4893_CR2","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/s40262-016-0432-1","volume":"56","author":"N Chen","year":"2017","unstructured":"Chen N, Zhou S, Palmisano M (2017) Clinical Pharmacokinetics and pharmacodynamics of lenalidomide. Clin Pharmacokinet 56:139\u2013152","journal-title":"Clin Pharmacokinet"},{"key":"4893_CR3","doi-asserted-by":"publisher","first-page":"E4819","DOI":"10.1073\/pnas.1317084110","volume":"110","author":"JB Zeldis","year":"2013","unstructured":"Zeldis JB, Carter TL, Knight RD, Hui J (2013) Pomalidomide is teratogenic in rats and rabbits and can be neurotoxic in humans. ProcNatlAcadSciUSA 110:E4819","journal-title":"ProcNatlAcadSciUSA"},{"key":"4893_CR4","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1056\/NEJMoa1402551","volume":"371","author":"L Benboubker","year":"2014","unstructured":"Benboubker L, Dimopoulos MA, Dispenzieri A et al (2014) Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. N Engl J Med 371:906\u2013917","journal-title":"N Engl J Med"},{"key":"4893_CR5","first-page":"254","volume":"96","author":"AA Chanan-Khan","year":"2012","unstructured":"Chanan-Khan AA, Lonial S, Weber D et al (2012) Lenalidomide in combination with dexamethasone improves survival and time-to-progression in patients >\/=65 years old with relapsed or refractory multiple myeloma. IntJHematol 96:254\u2013262","journal-title":"IntJHematol"},{"key":"4893_CR6","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1056\/NEJMoa070596","volume":"357","author":"DM Weber","year":"2007","unstructured":"Weber DM, Chen C, Niesvizky R et al (2007) Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 357:2133\u20132142","journal-title":"N Engl J Med"},{"key":"4893_CR7","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1056\/NEJMoa070594","volume":"357","author":"M Dimopoulos","year":"2007","unstructured":"Dimopoulos M, Spencer A, Attal M et al (2007) Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 357:2123\u20132132","journal-title":"N Engl J Med"},{"key":"4893_CR8","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1002\/bmc.466","volume":"19","author":"YJ Huang","year":"2005","unstructured":"Huang YJ, Liao JF, Tsai TH (2005) Concurrent determination of thalidomide in rat blood, brain and bile using multiple microdialysis coupled to liquid chromatography. Biomed Chromatogr 19:488\u2013493","journal-title":"Biomed Chromatogr"},{"key":"4893_CR9","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1007\/s00280-011-1781-y","volume":"69","author":"JA Muscal","year":"2012","unstructured":"Muscal JA, Sun Y, Nuchtern JG et al (2012) Plasma and cerebrospinal fluid pharmacokinetics of thalidomide and lenalidomide in nonhuman primates. Cancer Chemother Pharmacol 69:943\u2013947","journal-title":"Cancer Chemother Pharmacol"},{"key":"4893_CR10","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1208\/s12248-012-9401-2","volume":"14","author":"DM Rozewski","year":"2012","unstructured":"Rozewski DM, Herman SE, Towns WH 2nd et al (2012) Pharmacokinetics and tissue disposition of lenalidomide in mice. AAPS J 14:872\u2013882","journal-title":"AAPS J"},{"key":"4893_CR11","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1111\/bjh.12351","volume":"162","author":"S Anwer","year":"2013","unstructured":"Anwer S, Collings F, Trace K, Sun Y, Sternberg A (2013) Cerebrospinal fluid penetrance of lenalidomide in meningeal myeloma. Br J Haematol 162:281\u2013282","journal-title":"Br J Haematol"},{"key":"4893_CR12","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1200\/JCO.2010.31.3601","volume":"29","author":"KE Warren","year":"2011","unstructured":"Warren KE, Goldman S, Pollack IF et al (2011) Phase I trial of lenalidomide in pediatric patients with recurrent, refractory, or progressive primary CNS tumors: Pediatric Brain Tumor Consortium study PBTC-018. J Clin Oncol 29:324\u2013329","journal-title":"J Clin Oncol"},{"key":"4893_CR13","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1007\/s00280-012-1966-z","volume":"70","author":"N Chen","year":"2012","unstructured":"Chen N, Kasserra C, Reyes J, Liu L, Lau H (2012) Single-dose pharmacokinetics of lenalidomide in healthy volunteers: dose proportionality, food effect, and racial sensitivity. Cancer Chemother Pharmacol 70:717\u2013725","journal-title":"Cancer Chemother Pharmacol"},{"key":"4893_CR14","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1007\/s00280-011-1760-3","volume":"69","author":"N Chen","year":"2012","unstructured":"Chen N, Wen L, Lau H, Surapaneni S, Kumar G (2012) Pharmacokinetics, metabolism and excretion of [(14)C]-lenalidomide following oral administration in healthy male subjects. Cancer Chemother Pharmacol 69:789\u2013797","journal-title":"Cancer Chemother Pharmacol"},{"key":"4893_CR15","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1021\/tx4004215","volume":"27","author":"G Chowdhury","year":"2014","unstructured":"Chowdhury G, Shibata N, Yamazaki H, Guengerich FP (2014) Human cytochrome P450 oxidation of 5-hydroxythalidomide and pomalidomide, an amino analogue of thalidomide. Chem Res Toxicol 27:147\u2013156","journal-title":"Chem Res Toxicol"},{"key":"4893_CR16","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0169-409X(00)00128-9","volume":"46","author":"P Artursson","year":"2001","unstructured":"Artursson P, Palm K, Luthman K (2001) Caco-2 monolayers in experimental and theoretical predictions of drug transport. Adv Drug Deliv Rev 46:27\u201343","journal-title":"Adv Drug Deliv Rev"},{"key":"4893_CR17","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.ejps.2005.02.009","volume":"25","author":"S Neuhoff","year":"2005","unstructured":"Neuhoff S, Ungell AL, Zamora I, Artursson P (2005) pH-Dependent passive and active transport of acidic drugs across Caco-2 cell monolayers. Eur J Pharm Sci 25:211\u2013220","journal-title":"Eur J Pharm Sci"},{"key":"4893_CR18","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1023\/A:1025032511040","volume":"20","author":"S Neuhoff","year":"2003","unstructured":"Neuhoff S, Ungell AL, Zamora I, Artursson P (2003) pH-dependent bidirectional transport of weakly basic drugs across Caco-2 monolayers: implications for drug-drug interactions. Pharm Res 20:1141\u20131148","journal-title":"Pharm Res"},{"key":"4893_CR19","doi-asserted-by":"publisher","first-page":"2088","DOI":"10.1021\/acs.chemrestox.5b00381","volume":"28","author":"S Nishiyama","year":"2015","unstructured":"Nishiyama S, Suemizu H, Shibata N, Guengerich FP, Yamazaki H (2015) Simulation of human plasma concentrations of thalidomide and primary 5-hydroxylated metabolites explored with pharmacokinetic data in humanized TK-NOG mice. Chem Res Toxicol 28:2088\u20132090","journal-title":"Chem Res Toxicol"},{"key":"4893_CR20","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1080\/00498254.2016.1247218","volume":"47","author":"M Shimizu","year":"2017","unstructured":"Shimizu M, Suemizu H, Mitsui M, Shibata N, Guengerich FP, Yamazaki H (2017) Metabolic profiles of pomalidomide in human plasma simulated with pharmacokinetic data in control and humanized-liver mice. Xenobiotica 47:844\u2013848","journal-title":"Xenobiotica"},{"key":"4893_CR21","doi-asserted-by":"publisher","first-page":"369","DOI":"10.2131\/jts.43.369","volume":"43","author":"N Murayama","year":"2018","unstructured":"Murayama N, Suemizu H, Uehara S et al (2018) Association of pharmacokinetic profiles of lenalidomide in human plasma simulated using pharmacokinetic data in humanized-liver mice with liver toxicity detected by human serum albumin RNA. J Toxicol Sci 43:369\u2013375","journal-title":"J Toxicol Sci"},{"key":"4893_CR22","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.toxrep.2020.01.004","volume":"7","author":"Y Kamiya","year":"2020","unstructured":"Kamiya Y, Takaku H, Yamada R et al (2020) Determination and prediction of permeability across intestinal epithelial cell monolayer of a diverse range of industrial chemicals\/drugs for estimation of oral absorption as a putative marker of hepatotoxicity. Toxicol Rep 7:149\u2013154","journal-title":"Toxicol Rep"},{"key":"4893_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2021.114749","volume":"192","author":"Y Kamiya","year":"2021","unstructured":"Kamiya Y, Omura A, Hayasaka R et al (2021) Prediction of permeability across intestinal cell monolayers for 219 disparate chemicals using in vitro experimental coefficients in a pH gradient system and in silico analyses by trivariate linear regressions and machine learning. Biochem Pharmacol 192:114749","journal-title":"Biochem Pharmacol"},{"key":"4893_CR24","doi-asserted-by":"publisher","first-page":"343","DOI":"10.2131\/jts.42.343","volume":"42","author":"N Murayama","year":"2017","unstructured":"Murayama N, Kazuki Y, Satoh D et al (2017) Induction of human cytochrome P450 3A enzymes in cultured placental cells by thalidomide and relevance to bioactivation and toxicity. J Toxicol Sci 42:343\u2013348","journal-title":"J Toxicol Sci"},{"key":"4893_CR25","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.3390\/pharmaceutics13091484","volume":"13","author":"D Watanabe","year":"2021","unstructured":"Watanabe D, Nakagawa S, Morofuji Y et al (2021) Characterization of a primate blood-brain barrier co-culture model prepared from primary brain endothelial cells, pericytes and astrocytes. Pharmaceutics 13:1484","journal-title":"Pharmaceutics"},{"key":"4893_CR26","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1021\/acs.chemrestox.0c00336","volume":"34","author":"Y Kamiya","year":"2021","unstructured":"Kamiya Y, Handa K, Miura T et al (2021) In silico prediction of input parameters for simplified physiologically based pharmacokinetic models for estimating plasma, liver, and kidney exposures in rats after oral doses of 246 disparate chemicals. Chem Res Toxicol 34:507\u2013513","journal-title":"Chem Res Toxicol"},{"key":"4893_CR27","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1021\/acs.chemrestox.8b00307","volume":"32","author":"Y Kamiya","year":"2019","unstructured":"Kamiya Y, Otsuka S, Miura T et al (2019) Plasma and hepatic concentrations of chemicals after virtual oral administrations extrapolated using rat plasma data and simple physiologically based pharmacokinetic models. Chem Res Toxicol 32:211\u2013218","journal-title":"Chem Res Toxicol"},{"key":"4893_CR28","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1021\/acs.chemrestox.0c00009","volume":"33","author":"Y Kamiya","year":"2020","unstructured":"Kamiya Y, Otsuka S, Miura T et al (2020) Physiologically based pharmacokinetic models predicting renal and hepatic concentrations of industrial chemicals after virtual oral doses in rats. Chem Res Toxicol 33:1736\u20131751","journal-title":"Chem Res Toxicol"},{"key":"4893_CR29","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1002\/hon.1021","volume":"30","author":"SA Gangatharan","year":"2012","unstructured":"Gangatharan SA, Carney DA, Prince HM et al (2012) Emergence of central nervous system myeloma in the era of novel agents. Hematol Oncol 30:170\u2013174","journal-title":"Hematol Oncol"},{"key":"4893_CR30","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1182\/bloodadvances.2017014845","volume":"2","author":"JL Rubenstein","year":"2018","unstructured":"Rubenstein JL, Geng H, Fraser EJ et al (2018) Phase 1 investigation of lenalidomide\/rituximab plus outcomes of lenalidomide maintenance in relapsed CNS lymphoma. Blood Adv 2:1595\u20131607","journal-title":"Blood Adv"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-022-04893-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-022-04893-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-022-04893-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,13]],"date-time":"2022-08-13T05:23:15Z","timestamp":1660368195000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-022-04893-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,22]]},"references-count":30,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["4893"],"URL":"https:\/\/doi.org\/10.1007\/s00277-022-04893-w","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,22]]},"assertion":[{"value":"15 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were carried out in accordance with the ethical standards of the relevant institutional and\/or national research committees and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. The research was approved by the Ethical Committees of Tokai University School of Medicine (No. 20R-059) and Isehara Kyodo Hospital (No. 139). Informed consent was obtained from the patient.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}